{"id":3175,"date":"2022-02-07T16:24:20","date_gmt":"2022-02-07T15:24:20","guid":{"rendered":"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-has-been-selected-by-investhorizon-to-join-its-accelerator-programme\/"},"modified":"2022-02-07T16:24:20","modified_gmt":"2022-02-07T15:24:20","slug":"oacp-has-been-selected-by-investhorizon-to-join-its-accelerator-programme","status":"publish","type":"post","link":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/oacp-has-been-selected-by-investhorizon-to-join-its-accelerator-programme\/","title":{"rendered":"OaCP has been selected by InvestHorizon to join its accelerator programme"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.9.3&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;0px||||false|false&#8221; custom_padding=&#8221;0px|||||&#8221;][et_pb_row _builder_version=&#8221;4.9.3&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;0px||||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.9.3&#8243; _module_preset=&#8221;default&#8221;][et_pb_text _builder_version=&#8221;4.9.7&#8243; _module_preset=&#8221;default&#8221;]<\/p>\n<p>We&#8217;ve been <strong>selected by <a href=\"http:\/\/www.investhorizon.eu\/\">Invest Horizon Accelerator<\/a><\/strong> to join their accelerator Program, financed by the <a href=\"https:\/\/ec.europa.eu\/info\/index_en\"><strong>European Commission<\/strong><\/a>, in association with <strong>Eureka<\/strong>, to facilitate <strong>Series A funding for selected deep tech companies<\/strong> boosting their investment readiness and investor relations..<\/p>\n<p>Since its launch, InvestHorizon has selected 513 SMEs from 37 countries and this June has seen <strong>just 74 startups accepted<\/strong> in the 8th and last cohort.<\/p>\n<p>We are one of them and we&#8217;re looking forward to<strong> getting the best from this opportunity<\/strong> to reach <strong>new great results for everyone with our products<\/strong>.<\/p>\n<p><a href=\"https:\/\/investhorizon.eu\/news\/press\/press-release-investhorizon-accelerator-welcomes-74-deep-tech-startups-297\">[PRESS RELEASE] \u2013 InvestHorizon accelerator welcomes 74 deep tech startups | InvestHorizon &#8211; Fast Track to Series A Investment<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>We&#8217;ve been selected by Invest Horizon Accelerator to join their accelerator Program, financed by the European Commission, in association with Eureka, to facilitate Series A funding for selected deep tech companies boosting their investment readiness and investor relations.. Since its launch, InvestHorizon has selected 513 SMEs from 37 countries and this June has seen just [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":2725,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[43],"tags":[],"class_list":["post-3175","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-events-awards"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>OaCP has been selected by InvestHorizon to join its accelerator programme - OaCP<\/title>\n<meta name=\"description\" content=\"OaCP has been selected by InvestHorizon to join its accelerator programme, financed by the European Commission, in association with Eureka, to facilitate Series A funding for selected deep tech companies boosting their investment readiness and investor relations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OaCP has been selected by InvestHorizon to join its accelerator programme - OaCP\" \/>\n<meta property=\"og:description\" content=\"OaCP has been selected by InvestHorizon to join its accelerator programme, financed by the European Commission, in association with Eureka, to facilitate Series A funding for selected deep tech companies boosting their investment readiness and investor relations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/\" \/>\n<meta property=\"og:site_name\" content=\"OaCP\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-07T15:24:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2021\/07\/2019-InvestHorizon-Logo-Vertical-WebRGB-01.png\" \/>\n\t<meta property=\"og:image:width\" content=\"5692\" \/>\n\t<meta property=\"og:image:height\" content=\"3200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Andrea Faviere\" \/>\n<meta name=\"twitter:label1\" content=\"Scritto da\" \/>\n\t<meta name=\"twitter:data1\" content=\"Andrea Faviere\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/\"},\"author\":{\"name\":\"Andrea Faviere\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/person\/f3323e37ce648e6f8ebd51aba3e8cd08\"},\"headline\":\"OaCP has been selected by InvestHorizon to join its accelerator programme\",\"datePublished\":\"2022-02-07T15:24:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/\"},\"wordCount\":182,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2021\/07\/2019-InvestHorizon-Logo-Vertical-WebRGB-01.png\",\"articleSection\":[\"Events and Awards\"],\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/\",\"url\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/\",\"name\":\"OaCP has been selected by InvestHorizon to join its accelerator programme - OaCP\",\"isPartOf\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2021\/07\/2019-InvestHorizon-Logo-Vertical-WebRGB-01.png\",\"datePublished\":\"2022-02-07T15:24:20+00:00\",\"description\":\"OaCP has been selected by InvestHorizon to join its accelerator programme, financed by the European Commission, in association with Eureka, to facilitate Series A funding for selected deep tech companies boosting their investment readiness and investor relations.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/#primaryimage\",\"url\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2021\/07\/2019-InvestHorizon-Logo-Vertical-WebRGB-01.png\",\"contentUrl\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2021\/07\/2019-InvestHorizon-Logo-Vertical-WebRGB-01.png\",\"width\":5692,\"height\":3200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OaCP has been selected by InvestHorizon to join its accelerator programme\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#website\",\"url\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/\",\"name\":\"OaCP\",\"description\":\"Oncology and Cytogenetic Products\",\"publisher\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#organization\",\"name\":\"OACP IE LTD\",\"url\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2018\/10\/logo-OaCP.png\",\"contentUrl\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2018\/10\/logo-OaCP.png\",\"width\":159,\"height\":70,\"caption\":\"OACP IE LTD\"},\"image\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/person\/f3323e37ce648e6f8ebd51aba3e8cd08\",\"name\":\"Andrea Faviere\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/762e80340f20c117281bda8dc6c0fb77c59236bdfad2a5aea61701d78bf09501?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/762e80340f20c117281bda8dc6c0fb77c59236bdfad2a5aea61701d78bf09501?s=96&d=mm&r=g\",\"caption\":\"Andrea Faviere\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OaCP has been selected by InvestHorizon to join its accelerator programme - OaCP","description":"OaCP has been selected by InvestHorizon to join its accelerator programme, financed by the European Commission, in association with Eureka, to facilitate Series A funding for selected deep tech companies boosting their investment readiness and investor relations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/","og_locale":"it_IT","og_type":"article","og_title":"OaCP has been selected by InvestHorizon to join its accelerator programme - OaCP","og_description":"OaCP has been selected by InvestHorizon to join its accelerator programme, financed by the European Commission, in association with Eureka, to facilitate Series A funding for selected deep tech companies boosting their investment readiness and investor relations.","og_url":"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/","og_site_name":"OaCP","article_published_time":"2022-02-07T15:24:20+00:00","og_image":[{"width":5692,"height":3200,"url":"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2021\/07\/2019-InvestHorizon-Logo-Vertical-WebRGB-01.png","type":"image\/png"}],"author":"Andrea Faviere","twitter_misc":{"Scritto da":"Andrea Faviere","Tempo di lettura stimato":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/#article","isPartOf":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/"},"author":{"name":"Andrea Faviere","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/person\/f3323e37ce648e6f8ebd51aba3e8cd08"},"headline":"OaCP has been selected by InvestHorizon to join its accelerator programme","datePublished":"2022-02-07T15:24:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/"},"wordCount":182,"commentCount":0,"publisher":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#organization"},"image":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/#primaryimage"},"thumbnailUrl":"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2021\/07\/2019-InvestHorizon-Logo-Vertical-WebRGB-01.png","articleSection":["Events and Awards"],"inLanguage":"it-IT","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/","url":"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/","name":"OaCP has been selected by InvestHorizon to join its accelerator programme - OaCP","isPartOf":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/#primaryimage"},"image":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/#primaryimage"},"thumbnailUrl":"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2021\/07\/2019-InvestHorizon-Logo-Vertical-WebRGB-01.png","datePublished":"2022-02-07T15:24:20+00:00","description":"OaCP has been selected by InvestHorizon to join its accelerator programme, financed by the European Commission, in association with Eureka, to facilitate Series A funding for selected deep tech companies boosting their investment readiness and investor relations.","breadcrumb":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/#primaryimage","url":"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2021\/07\/2019-InvestHorizon-Logo-Vertical-WebRGB-01.png","contentUrl":"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2021\/07\/2019-InvestHorizon-Logo-Vertical-WebRGB-01.png","width":5692,"height":3200},{"@type":"BreadcrumbList","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/oacp-investhorizon-accelerator-programme\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/"},{"@type":"ListItem","position":2,"name":"OaCP has been selected by InvestHorizon to join its accelerator programme"}]},{"@type":"WebSite","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#website","url":"https:\/\/www.oncology-and-cytogenetic-products.com\/","name":"OaCP","description":"Oncology and Cytogenetic Products","publisher":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.oncology-and-cytogenetic-products.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#organization","name":"OACP IE LTD","url":"https:\/\/www.oncology-and-cytogenetic-products.com\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2018\/10\/logo-OaCP.png","contentUrl":"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2018\/10\/logo-OaCP.png","width":159,"height":70,"caption":"OACP IE LTD"},"image":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/person\/f3323e37ce648e6f8ebd51aba3e8cd08","name":"Andrea Faviere","image":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/762e80340f20c117281bda8dc6c0fb77c59236bdfad2a5aea61701d78bf09501?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/762e80340f20c117281bda8dc6c0fb77c59236bdfad2a5aea61701d78bf09501?s=96&d=mm&r=g","caption":"Andrea Faviere"}}]}},"_links":{"self":[{"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/posts\/3175","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/comments?post=3175"}],"version-history":[{"count":2,"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/posts\/3175\/revisions"}],"predecessor-version":[{"id":3177,"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/posts\/3175\/revisions\/3177"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/media\/2725"}],"wp:attachment":[{"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/media?parent=3175"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/categories?post=3175"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/tags?post=3175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}